A 12‐Week, Double‐Blind, Placebo‐Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI‐1027 in Patients With Low HDL‐C and Either Normal or Elevated Triglycerides

Trial Profile

A 12‐Week, Double‐Blind, Placebo‐Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI‐1027 in Patients With Low HDL‐C and Either Normal or Elevated Triglycerides

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2016

At a glance

  • Drugs Gemcabene (Primary)
  • Indications Hypercholesterolaemia; Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Sponsors Gemphire Therapeutics
  • Most Recent Events

    • 31 Oct 2016 Results published in Gemphire Therapeutics media release.
    • 15 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top